Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AEMD 
Aethlon Medical Inc (AEMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: AEMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.14% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.17M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 1 | Beta 1.88 | 52 Weeks Range 1.10 - 8.44 | Updated Date 07/10/2025 |
52 Weeks Range 1.10 - 8.44 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-27 | When - | Estimate -1.11 | Actual -3.44 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.82% | Return on Equity (TTM) -245.88% |
Valuation
Trailing PE - | Forward PE 0.21 | Enterprise Value -1102802 | Price to Sales(TTM) 2.37 |
Enterprise Value -1102802 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 1.07 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2585320 | Shares Floating 1735388 |
Shares Outstanding 2585320 | Shares Floating 1735388 | ||
Percent Insiders 0.94 | Percent Institutions 21.15 |
Upturn AI SWOT
Aethlon Medical Inc
Company Overview
History and Background
Aethlon Medical, Inc. was founded in 1991. It is a medical technology company focused on developing therapeutic devices to address unmet needs in global health and biodefense. The company has primarily focused on its Hemopurifieru00ae technology.
Core Business Areas
- Therapeutic Blood Filtration: Aethlon Medical's core business revolves around developing and commercializing the Hemopurifieru00ae, a device designed to remove harmful substances from the bloodstream.
Leadership and Structure
Aethlon Medical's leadership consists of a board of directors and an executive team. The specific structure and individuals change over time; refer to the company's website or SEC filings for the most current information.
Top Products and Market Share
Key Offerings
- Hemopurifieru00ae: The Hemopurifieru00ae is a blood filtration device designed to remove viruses and exosomes from the circulation. It has been investigated in clinical studies for various infectious diseases and cancer. Market share data and revenue figures are not publicly available. Competitors include companies developing blood purification technologies and therapies for the targeted diseases, though the Hemopurifier's specific mechanism is somewhat unique.
Market Dynamics
Industry Overview
The therapeutic blood filtration industry is characterized by innovation in materials science, engineering, and medicine. It caters to a wide range of conditions, from infectious diseases to cancer. The industry is subject to strict regulatory oversight and requires extensive clinical trials for product approval.
Positioning
Aethlon Medical occupies a niche position within the therapeutic blood filtration industry, focusing on broad-spectrum removal of pathogens and exosomes. Its competitive advantage lies in its unique Hemopurifieru00ae technology.
Total Addressable Market (TAM)
The TAM for blood purification technologies is estimated to be in the billions of dollars. Aethlon's positioning allows it to target specific segments within this large market, such as viral diseases and oncology.
Upturn SWOT Analysis
Strengths
- Novel Hemopurifieru00ae technology
- Potential for broad-spectrum pathogen removal
- Investigational device exemption (IDE) approval for certain indications
- Experienced management team
Weaknesses
- Reliance on a single product
- Limited commercialization success to date
- Significant capital requirements
- Dependence on regulatory approvals
- Lack of consistent revenue streams
Opportunities
- Expansion into new therapeutic areas
- Partnerships with pharmaceutical companies
- Government funding for biodefense applications
- Addressing unmet needs in emerging markets
Threats
- Competition from established medical device companies
- Regulatory hurdles and delays
- Clinical trial failures
- Difficulty securing funding
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Baxter International Inc (BAX)
- Fresenius Medical Care AG & Co. KGaA (FMS)
- Asahi Kasei Corporation (3407.T)
Competitive Landscape
Aethlon Medical faces competition from larger, more established medical device companies with greater resources. Its advantage lies in its novel technology, but it needs to demonstrate clinical efficacy and secure regulatory approvals to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Aethlon Medical's growth has been primarily driven by research and development activities rather than revenue generation.
Future Projections: Future growth depends on the successful commercialization of the Hemopurifieru00ae and the development of new applications. Analyst estimates are subject to change.
Recent Initiatives: Recent initiatives may include clinical trials, regulatory submissions, and partnerships. Refer to the company's press releases and investor presentations for updates.
Summary
Aethlon Medical is a developmental-stage company with a novel blood filtration technology. Its success hinges on the successful commercialization of the Hemopurifieru00ae, which requires positive clinical trial results and regulatory approvals. The company faces significant financial and competitive challenges. However, partnerships and government funding could boost their market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q)
- Company Website
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aethlon Medical Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2001-01-02 | CEO, CFO, Secretary & Director Mr. James B. Frakes M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.aethlonmedical.com |
Full time employees - | Website https://www.aethlonmedical.com | ||
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening viral infectious, diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.